Drug-eluting stents - Safety concerns

Clinical Cardiology

Volumn 29, Issue 11, 2006, Pages 479-480

  Conti, C Richard ^a  

^a NONE

Author keywords

Bare metal stents; Drug eluting stents; Stent thrombosis

Indexed keywords

BLEEDING; DRUG ELUTING STENT; EDITORIAL; MORTALITY; SAFETY; THROMBOSIS;

CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; SAFETY; SIROLIMUS; STENTS;

EID: 33750804764     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960291102     Document Type: Editorial

References (5)

1. Virmani R: The Downside of Drug-Eluting Stents. ACCEL interview with Lawrence Bonchek. Sept. 2003
2. Pfisterer MD: Late clinical events related to late stent thrombosis after stopping clopidogrel. (BASKET LATE trial). Cardiosource: Presented at the March 2006 ACC Annual Scientific Session, Atlanta, GA
3. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R: Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202
4. Yock CA, Isbill JM, King SB: Bare-metal stent outcomes in an unselected patient population. Clin Card 2006;29(8):352-356
5. Takano M, Takayoshi O, Inami S, Seimiya K, Sakai S, Mizuno K: Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. Eur Heart J 2006;27:2189-2195